Cells with amplified HER2 gene need to be considered carefully, study says

[News]

Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells and circulating tumor DNA in cancer patients, reported the publication in the journal Cancer Medicine of a paper entitled "Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer" on research performed with collaborators from the University of Texas MD Anderson Cancer Center.

More... (http://www.news-medical.net/news/20130605/Cells-with-amplified-HER2-gene-need-to-be-considered-carefully-study-says.aspx)